All

What are you looking for?

All
Projects
Results
Organizations

Quick search

  • Projects supported by TA ČR
  • Excellent projects
  • Projects with the highest public support
  • Current projects

Smart search

  • That is how I find a specific +word
  • That is how I leave the -word out of the results
  • “That is how I can find the whole phrase”

Third-generation taxanes SB-T-121605 and SB-T-121606 are effective in pancreatic ductal adenocarcinoma

The result's identifiers

  • Result code in IS VaVaI

    <a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F86652036%3A_____%2F24%3A00584812" target="_blank" >RIV/86652036:_____/24:00584812 - isvavai.cz</a>

  • Alternative codes found

    RIV/00216208:11120/24:43926666 RIV/00216208:11140/24:10475509 RIV/00064173:_____/24:43926666

  • Result on the web

    <a href="https://www.sciencedirect.com/science/article/pii/S2589004224002657?via%3Dihub" target="_blank" >https://www.sciencedirect.com/science/article/pii/S2589004224002657?via%3Dihub</a>

  • DOI - Digital Object Identifier

    <a href="http://dx.doi.org/10.1016/j.isci.2024.109044" target="_blank" >10.1016/j.isci.2024.109044</a>

Alternative languages

  • Result language

    angličtina

  • Original language name

    Third-generation taxanes SB-T-121605 and SB-T-121606 are effective in pancreatic ductal adenocarcinoma

  • Original language description

    Pancreatic cancer is a severe malignancy with increasing incidence and high mortality due to late diagnosis and low sensitivity to treatments. Search for the most appropriate drugs and therapeutic regimens is the most promising way to improve the treatment outcomes of the patients. This study aimed to compare (1) in vitro efficacy and (2) in vivo antitumor effects of conventional paclitaxel and the newly synthesized second (SB-T-1216) and third (SB-T-121605 and SB-T-121606) generation taxanes in KRAS wild type BxPC-3 and more aggressive KRAS G12V mutated Paca-44 pancreatic cancer cell line models. In vitro, paclitaxel efficacy was 27.6 G 1.7 nM, while SB-Ts showed 1.7-7.4 times higher efficacy. Incorporation of SB-T121605 and SB-T-121606 into in vivo therapeutic regimens containing paclitaxel was effective in suppressing tumor growth in Paca-44 tumorbearing mice at small doses (%3 mg/kg). SB-T-121605 and SB-T121606 in combination with paclitaxel are promising candidates for the next phase of preclinical testing.

  • Czech name

  • Czech description

Classification

  • Type

    J<sub>imp</sub> - Article in a specialist periodical, which is included in the Web of Science database

  • CEP classification

  • OECD FORD branch

    10608 - Biochemistry and molecular biology

Result continuities

  • Project

    Result was created during the realization of more than one project. More information in the Projects tab.

  • Continuities

    I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Others

  • Publication year

    2024

  • Confidentiality

    S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Data specific for result type

  • Name of the periodical

    iScience

  • ISSN

    2589-0042

  • e-ISSN

    2589-0042

  • Volume of the periodical

    27

  • Issue of the periodical within the volume

    2

  • Country of publishing house

    US - UNITED STATES

  • Number of pages

    15

  • Pages from-to

    109044

  • UT code for WoS article

    001182148700001

  • EID of the result in the Scopus database

    2-s2.0-85184767975